Literature DB >> 3029306

Beta 2 microglobulin enhances the infectivity of cytomegalovirus and when bound to the virus enables class I HLA molecules to be used as a virus receptor.

J E Grundy, J A McKeating, P J Ward, A R Sanderson, P D Griffiths.   

Abstract

We have previously demonstrated that human cytomegalovirus (CMV) binds the host protein beta 2 microglobulin (beta 2m) from body fluids or from cell culture media. In this report we have examined the effect of the beta 2m on viral infectivity. We have shown that the addition of human purified beta 2m, or a fraction of foetal calf serum corresponding to bovine beta 2m, to culture medium increased the amount of infectious extracellular CMV, compared to that from cells grown in serum-free medium. Metabolic labelling experiments demonstrated that this effect was not due to an increase in the amount of extracellular virus but to an increase in the infectivity of the virus present in extracellular fluids. We concluded that the binding of beta 2m by CMV increased its infectivity. We have shown that CMV and beta 2m compete for binding sites on fibroblasts. As the main binding site on cells for beta 2m is the class I HLA heavy chain we compared the binding of CMV to the Raji and Daudi cell lines which express or lack expression of class I HLA molecules. The binding of radiolabelled beta 2m-coated CMV was significantly higher to Raji cells than to Daudi cells. Furthermore, CMV could compete with beta 2m for binding to Raji cells, although the reverse was not true. These results demonstrate that CMV can use class I HLA molecules as a virus receptor. We propose that when coated with beta 2m, CMV has the capacity to displace beta 2m from the class I HLA heavy chain-beta 2m dimer on the cell surface and bind to cells. The fact that beta 2m enhances infectivity suggests that such binding leads to productive infection of cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029306     DOI: 10.1099/0022-1317-68-3-793

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  42 in total

1.  Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus.

Authors:  S Keay; T C Merigan; L Rasmussen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  The human fibroblast receptor for gp86 of human cytomegalovirus is a phosphorylated glycoprotein.

Authors:  S Keay; B Baldwin
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

4.  The effects of protein malnutrition on the pathogenesis of murine cytomegalovirus disease.

Authors:  H K Teo; P Price; J M Papadimitriou
Journal:  Int J Exp Pathol       Date:  1991-02       Impact factor: 1.925

5.  An Fc receptor for human immunoglobulin G is located within the tegument of human cytomegalovirus.

Authors:  L M Stannard; D R Hardie
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

6.  Proteins associated with purified human cytomegalovirus particles.

Authors:  C J Baldick; T Shenk
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 7.  The status of CMV as a human pathogen.

Authors:  P D Griffiths; J E Grundy
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

8.  CD13 (human aminopeptidase N) mediates human cytomegalovirus infection.

Authors:  C Söderberg; T D Giugni; J A Zaia; S Larsson; J M Wahlberg; E Möller
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Replication of human cytomegalovirus in the cells of the U937 monocytoid cell line.

Authors:  K Numazaki; N Nagata; T Sato; S Chiba
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

10.  Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein.

Authors:  A Gallina; L Simoncini; S Garbelli; E Percivalle; G Pedrali-Noy; K S Lee; R L Erikson; B Plachter; G Gerna; G Milanesi
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.